A citation-based method for searching scientific literature

Ezra Y Rosen, Melissa L Johnson, Sarah E Clifford, Romel Somwar, Jennifer F Kherani, Jieun Son, Arrien A Bertram, Monika A Davare, Eric Gladstone, Elena V Ivanova, Dahlia N Henry, Elaine M Kelley, Mika Lin, Marina S D Milan, Binoj C Nair, Elizabeth A Olek, Jenna E Scanlon, Morana Vojnic, Kevin Ebata, Jaclyn F Hechtman, Bob T Li, Lynette M Sholl, Barry S Taylor, Marc Ladanyi, Pasi A Jänne, S Michael Rothenberg, Alexander Drilon, Geoffrey R Oxnard. Clin Cancer Res 2021
Times Cited: 49







List of co-cited articles
483 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Mechanisms of resistance to selective RET tyrosine kinase inhibitors in RET fusion-positive non-small-cell lung cancer.
J J Lin, S V Liu, C E McCoach, V W Zhu, A C Tan, S Yoda, J Peterson, A Do, K Prutisto-Chang, I Dagogo-Jack,[...]. Ann Oncol 2020
83
77

Efficacy of Selpercatinib in RET Fusion-Positive Non-Small-Cell Lung Cancer.
Alexander Drilon, Geoffrey R Oxnard, Daniel S W Tan, Herbert H F Loong, Melissa Johnson, Justin Gainor, Caroline E McCoach, Oliver Gautschi, Benjamin Besse, Byoung C Cho,[...]. N Engl J Med 2020
276
67

RET Solvent Front Mutations Mediate Acquired Resistance to Selective RET Inhibition in RET-Driven Malignancies.
Benjamin J Solomon, Lavinia Tan, Jessica J Lin, Stephen Q Wong, Sebastian Hollizeck, Kevin Ebata, Brian B Tuch, Satoshi Yoda, Justin F Gainor, Lecia V Sequist,[...]. J Thorac Oncol 2020
117
63

Structural basis of acquired resistance to selpercatinib and pralsetinib mediated by non-gatekeeper RET mutations.
V Subbiah, T Shen, S S Terzyan, X Liu, X Hu, K P Patel, M Hu, M Cabanillas, A Behrang, F Meric-Bernstam,[...]. Ann Oncol 2021
75
51

Selective RET kinase inhibition for patients with RET-altered cancers.
V Subbiah, V Velcheti, B B Tuch, K Ebata, N L Busaidy, M E Cabanillas, L J Wirth, S Stock, S Smith, V Lauriault,[...]. Ann Oncol 2018
219
36

Precision Targeted Therapy with BLU-667 for RET-Driven Cancers.
Vivek Subbiah, Justin F Gainor, Rami Rahal, Jason D Brubaker, Joseph L Kim, Michelle Maynard, Wei Hu, Qiongfang Cao, Michael P Sheets, Douglas Wilson,[...]. Cancer Discov 2018
224
36

Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry.
Oliver Gautschi, Julie Milia, Thomas Filleron, Juergen Wolf, David P Carbone, Dwight Owen, Ross Camidge, Vignhesh Narayanan, Robert C Doebele, Benjamin Besse,[...]. J Clin Oncol 2017
215
34

Frequency of Brain Metastases and Multikinase Inhibitor Outcomes in Patients With RET-Rearranged Lung Cancers.
Alexander Drilon, Jessica J Lin, Thomas Filleron, Ai Ni, Julie Milia, Isabella Bergagnini, Vaios Hatzoglou, Vamsidhar Velcheti, Michael Offin, Bob Li,[...]. J Thorac Oncol 2018
83
32

Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial.
Alexander Drilon, Natasha Rekhtman, Maria Arcila, Lu Wang, Andy Ni, Melanie Albano, Martine Van Voorthuysen, Romel Somwar, Roger S Smith, Joseph Montecalvo,[...]. Lancet Oncol 2016
295
30

Efficacy of Selpercatinib in RET-Altered Thyroid Cancers.
Lori J Wirth, Eric Sherman, Bruce Robinson, Benjamin Solomon, Hyunseok Kang, Jochen Lorch, Francis Worden, Marcia Brose, Jyoti Patel, Sophie Leboulleux,[...]. N Engl J Med 2020
237
28

Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes.
Alexander Drilon, Zishuo I Hu, Gillianne G Y Lai, Daniel S W Tan. Nat Rev Clin Oncol 2018
156
28

RET fusions define a unique molecular and clinicopathologic subtype of non-small-cell lung cancer.
Rui Wang, Haichuan Hu, Yunjian Pan, Yuan Li, Ting Ye, Chenguang Li, Xiaoyang Luo, Lei Wang, Hang Li, Yang Zhang,[...]. J Clin Oncol 2012
365
28

Landscape of Acquired Resistance to Osimertinib in EGFR-Mutant NSCLC and Clinical Validation of Combined EGFR and RET Inhibition with Osimertinib and BLU-667 for Acquired RET Fusion.
Zofia Piotrowska, Hideko Isozaki, Jochen K Lennerz, Justin F Gainor, Inga T Lennes, Viola W Zhu, Nicolas Marcoux, Mandeep K Banwait, Subba R Digumarthy, Wenjia Su,[...]. Cancer Discov 2018
251
26

Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry.
J Mazieres, A Drilon, A Lusque, L Mhanna, A B Cortot, L Mezquita, A A Thai, C Mascaux, S Couraud, R Veillon,[...]. Ann Oncol 2019
507
26

Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study.
Justin F Gainor, Giuseppe Curigliano, Dong-Wan Kim, Dae Ho Lee, Benjamin Besse, Christina S Baik, Robert C Doebele, Philippe A Cassier, Gilberto Lopes, Daniel S W Tan,[...]. Lancet Oncol 2021
97
26

Vandetanib in patients with previously treated RET-rearranged advanced non-small-cell lung cancer (LURET): an open-label, multicentre phase 2 trial.
Kiyotaka Yoh, Takashi Seto, Miyako Satouchi, Makoto Nishio, Noboru Yamamoto, Haruyasu Murakami, Naoyuki Nogami, Shingo Matsumoto, Takashi Kohno, Koji Tsuta,[...]. Lancet Respir Med 2017
211
24

Responsiveness to immune checkpoint inhibitors versus other systemic therapies in RET-aberrant malignancies.
Aparna Hegde, Alexander Y Andreev-Drakhlin, Jason Roszik, Le Huang, Shuang Liu, Kenneth Hess, Maria Cabanillas, Mimi I Hu, Naifa L Busaidy, Steven I Sherman,[...]. ESMO Open 2020
28
42

Resistance to RET-Inhibition in RET-Rearranged NSCLC Is Mediated By Reactivation of RAS/MAPK Signaling.
Sarah K Nelson-Taylor, Anh T Le, Minjae Yoo, Laura Schubert, Katie M Mishall, Andrea Doak, Marileila Varella-Garcia, Aik-Choon Tan, Robert C Doebele. Mol Cancer Ther 2017
51
22

RET Aberrations in Diverse Cancers: Next-Generation Sequencing of 4,871 Patients.
Shumei Kato, Vivek Subbiah, Erica Marchlik, Sheryl K Elkin, Jennifer L Carter, Razelle Kurzrock. Clin Cancer Res 2017
124
22

Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies.
Doron Lipson, Marzia Capelletti, Roman Yelensky, Geoff Otto, Alex Parker, Mirna Jarosz, John A Curran, Sohail Balasubramanian, Troy Bloom, Kristina W Brennan,[...]. Nat Med 2012
630
22

RET revisited: expanding the oncogenic portfolio.
Lois M Mulligan. Nat Rev Cancer 2014
309
22

State-of-the-Art Strategies for Targeting RET-Dependent Cancers.
Vivek Subbiah, Dong Yang, Vamsidhar Velcheti, Alexander Drilon, Funda Meric-Bernstam. J Clin Oncol 2020
101
22

A Phase I/Ib Trial of the VEGFR-Sparing Multikinase RET Inhibitor RXDX-105.
Alexander Drilon, Siqing Fu, Manish R Patel, Marwan Fakih, Ding Wang, Anthony J Olszanski, Daniel Morgensztern, Stephen V Liu, Byoung Chul Cho, Lyudmila Bazhenova,[...]. Cancer Discov 2019
77
20

Drug resistance profiles of mutations in the RET kinase domain.
Xuan Liu, Tao Shen, Blaine H M Mooers, Frank Hilberg, Jie Wu. Br J Pharmacol 2018
43
23

Emergence of a RET V804M Gatekeeper Mutation During Treatment With Vandetanib in RET-Rearranged NSCLC.
Ibiayi Dagogo-Jack, Sara E Stevens, Jessica J Lin, Rebecca Nagy, Lorin Ferris, Alice T Shaw, Justin F Gainor. J Thorac Oncol 2018
35
28

Clinical and Translational Implications of RET Rearrangements in Non-Small Cell Lung Cancer.
Roberto Ferrara, Nathalie Auger, Edouard Auclin, Benjamin Besse. J Thorac Oncol 2018
108
20

Cabozantinib in progressive medullary thyroid cancer.
Rossella Elisei, Martin J Schlumberger, Stefan P Müller, Patrick Schöffski, Marcia S Brose, Manisha H Shah, Lisa Licitra, Barbara Jarzab, Viktor Medvedev, Michael C Kreissl,[...]. J Clin Oncol 2013
695
20

Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial.
Samuel A Wells, Bruce G Robinson, Robert F Gagel, Henning Dralle, James A Fagin, Massimo Santoro, Eric Baudin, Rossella Elisei, Barbara Jarzab, James R Vasselli,[...]. J Clin Oncol 2012
889
20

Vandetanib in pretreated patients with advanced non-small cell lung cancer-harboring RET rearrangement: a phase II clinical trial.
S-H Lee, J-K Lee, M-J Ahn, D-W Kim, J-M Sun, B Keam, T M Kim, D S Heo, J S Ahn, Y-L Choi,[...]. Ann Oncol 2017
146
20

A phase 2 study of lenvatinib in patients with RET fusion-positive lung adenocarcinoma.
Toyoaki Hida, Vamsidhar Velcheti, Karen L Reckamp, Hiroshi Nokihara, Pallavi Sachdev, Tomoki Kubota, Takuya Nakada, Corina E Dutcus, Min Ren, Tomohide Tamura. Lung Cancer 2019
53
20

Patient-driven discovery and post-clinical validation of NTRK3 fusion as an acquired resistance mechanism to selpercatinib in RET fusion-positive lung cancer.
V Subbiah, T Shen, M Tetzlaff, A Weissferdt, L A Byers, T Cascone, A Behrang, F Meric-Bernstam, B H M Mooers, S M Rothenberg,[...]. Ann Oncol 2021
14
71

Emergence of High Level of MET Amplification as Off-Target Resistance to Selpercatinib Treatment in KIF5B-RET NSCLC.
Viola W Zhu, Russell Madison, Alexa B Schrock, Sai-Hong Ignatius Ou. J Thorac Oncol 2020
18
50

KIF5B-RET fusions in lung adenocarcinoma.
Takashi Kohno, Hitoshi Ichikawa, Yasushi Totoki, Kazuki Yasuda, Masaki Hiramoto, Takao Nammo, Hiromi Sakamoto, Koji Tsuta, Koh Furuta, Yoko Shimada,[...]. Nat Med 2012
588
18

RET, ROS1 and ALK fusions in lung cancer.
Kengo Takeuchi, Manabu Soda, Yuki Togashi, Ritsuro Suzuki, Seiji Sakata, Satoko Hatano, Reimi Asaka, Wakako Hamanaka, Hironori Ninomiya, Hirofumi Uehara,[...]. Nat Med 2012
922
18


Immunophenotype and Response to Immunotherapy of RET-Rearranged Lung Cancers.
Michael Offin, Robin Guo, Stephanie L Wu, Joshua Sabari, Josiah D Land, Ai Ni, Joseph Montecalvo, Darragh F Halpenny, Larry W Buie, Terry Pak,[...]. JCO Precis Oncol 2019
62
18

A secondary RET mutation in the activation loop conferring resistance to vandetanib.
Takashi Nakaoku, Takashi Kohno, Mitsugu Araki, Seiji Niho, Rakhee Chauhan, Phillip P Knowles, Katsuya Tsuchihara, Shingo Matsumoto, Yoko Shimada, Sachiyo Mimaki,[...]. Nat Commun 2018
61
16

Advances in Targeting RET-Dependent Cancers.
Vivek Subbiah, Gilbert J Cote. Cancer Discov 2020
55
16

Structure and chemical inhibition of the RET tyrosine kinase domain.
Phillip P Knowles, Judith Murray-Rust, Svend Kjaer, Rizaldy P Scott, Sarah Hanrahan, Massimo Santoro, Carlos F Ibáñez, Neil Q McDonald. J Biol Chem 2006
179
16

Pralsetinib: First Approval.
Anthony Markham. Drugs 2020
42
19

MET Alterations Are a Recurring and Actionable Resistance Mechanism in ALK-Positive Lung Cancer.
Ibiayi Dagogo-Jack, Satoshi Yoda, Jochen K Lennerz, Adam Langenbucher, Jessica J Lin, Marguerite M Rooney, Kylie Prutisto-Chang, Audris Oh, Nathaniel A Adams, Beow Y Yeap,[...]. Clin Cancer Res 2020
79
16

A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing.
Young Seok Ju, Won-Chul Lee, Jong-Yeon Shin, Seungbok Lee, Thomas Bleazard, Jae-Kyung Won, Young Tae Kim, Jong-Il Kim, Jin-Hyoung Kang, Jeong-Sun Seo. Genome Res 2012
352
16

Disease associated mutations at valine 804 in the RET receptor tyrosine kinase confer resistance to selective kinase inhibitors.
Francesca Carlomagno, Teresa Guida, Suresh Anaganti, Giancarlo Vecchio, Alfredo Fusco, Anderson J Ryan, Marc Billaud, Massimo Santoro. Oncogene 2004
190
16

ESMO recommendations on the standard methods to detect RET fusions and mutations in daily practice and clinical research.
C Belli, F Penault-Llorca, M Ladanyi, N Normanno, J-Y Scoazec, L Lacroix, J S Reis-Filho, V Subbiah, J F Gainor, V Endris,[...]. Ann Oncol 2021
41
19

Clinical outcomes with pemetrexed-based systemic therapies in RET-rearranged lung cancers.
A Drilon, I Bergagnini, L Delasos, J Sabari, K M Woo, A Plodkowski, L Wang, M D Hellmann, P Joubert, C S Sima,[...]. Ann Oncol 2016
71
16


Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study.
Vivek Subbiah, Mimi I Hu, Lori J Wirth, Martin Schuler, Aaron S Mansfield, Giuseppe Curigliano, Marcia S Brose, Viola W Zhu, Sophie Leboulleux, Daniel W Bowles,[...]. Lancet Diabetes Endocrinol 2021
90
16

Lenvatinib versus placebo in radioiodine-refractory thyroid cancer.
Martin Schlumberger, Makoto Tahara, Lori J Wirth, Bruce Robinson, Marcia S Brose, Rossella Elisei, Mouhammed Amir Habra, Kate Newbold, Manisha H Shah, Ana O Hoff,[...]. N Engl J Med 2015
16

A comprehensive overview of the role of the RET proto-oncogene in thyroid carcinoma.
Cristina Romei, Raffaele Ciampi, Rossella Elisei. Nat Rev Endocrinol 2016
182
16

Overall survival analysis of EXAM, a phase III trial of cabozantinib in patients with radiographically progressive medullary thyroid carcinoma.
M Schlumberger, R Elisei, S Müller, P Schöffski, M Brose, M Shah, L Licitra, J Krajewska, M C Kreissl, B Niederle,[...]. Ann Oncol 2017
101
16


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.